Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

The immune microenvironment of hepatocellular carcinoma (HCC) is poorly characterized.
Combining two single-cell RNA sequencing technologies, we produced transcriptomes of …

Recent clinical successes of cancer immunotherapy necessitate the investigation of the
interaction between malignant cells and the host immune system. However, elucidation of …

Tumours comprise a heterogeneous collection of cells with distinct genetic and phenotypic
properties that can differentially promote progression, metastasis and drug resistance …

We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from
bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor …

Systematically tracking the tumor immunophenotype is required to understand the
mechanisms of cancer immunity and improve clinical benefit of cancer immunotherapy …

Immune cells infiltrating tumors can have important impact on tumor progression and
response to therapy. We present an efficient algorithm to simultaneously estimate the …

Summary The Cancer Genome Atlas revealed the genomic landscapes of human cancers.
In parallel, immunotherapy is transforming the treatment of advanced cancers. Unfortunately …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …